Prof. Malin Lindstedt and Dr. Christina Sakellariou have contributed with four key publications on a special issue of the Journal of Immunotoxicology on the “Immune-related adverse outcome pathways for immunomodulatory biotherapeutics”.

The issue publications are examples of the exiting collaboration of the imSAVAR project partners, who brought their unique expertise to explore how Adverse Outcome Pathways (AOPs) can revolutionize the regulatory development of cutting-edge therapies, such as IL-2 and CAR T-cells.

Preclinical safety assessment of modern immunomodulatory drugs and ATMPs (cell and gene therapies) poses significant challenges. Through the imSAVAR project, the team has worked diligently to create a systematic framework using immune-related AOPs (irAOPs) to identify risks efficiently and accelerate the preclinical evaluation process, thereby allowing for more efficient translation of research into clinical practice.

Learn more on issue on the journal's web site.